197 related articles for article (PubMed ID: 23638631)
1. Hormone withdrawal-associated symptoms: comparison of oestradiol valerate/dienogest versus ethinylestradiol/norgestimate.
Jensen JT; Parke S; Mellinger U; Serrani M; Mabey RG
Eur J Contracept Reprod Health Care; 2013 Aug; 18(4):274-83. PubMed ID: 23638631
[TBL] [Abstract][Full Text] [Related]
2. Effects of a combined oral contraceptive containing oestradiol valerate/dienogest on hormone withdrawal-associated symptoms: results from the multicentre, randomised, double-blind, active-controlled HARMONY II study.
Macìas G; Merki-Feld GS; Parke S; Mellinger U; Serrani M
J Obstet Gynaecol; 2013 Aug; 33(6):591-6. PubMed ID: 23919857
[TBL] [Abstract][Full Text] [Related]
3. Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel.
Ahrendt HJ; Makalová D; Parke S; Mellinger U; Mansour D
Contraception; 2009 Nov; 80(5):436-44. PubMed ID: 19835717
[TBL] [Abstract][Full Text] [Related]
4. Pelvic pain and quality of life of women with endometriosis during quadriphasic estradiol valerate/dienogest oral contraceptive: a patient-preference prospective 24-week pilot study.
Grandi G; Xholli A; Napolitano A; Palma F; Cagnacci A
Reprod Sci; 2015 May; 22(5):626-32. PubMed ID: 25394646
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of an oral contraceptive containing oestradiol valerate and dienogest.
Zeun S; Lu M; Uddin A; Zeiler B; Morrison D; Blode H
Eur J Contracept Reprod Health Care; 2009 Jun; 14(3):221-32. PubMed ID: 19565420
[TBL] [Abstract][Full Text] [Related]
6. Effect of a contraceptive pill containing estradiol valerate and dienogest (E2V/DNG) in women with menstrually-related migraine (MRM).
Nappi RE; Terreno E; Sances G; Martini E; Tonani S; Santamaria V; Tassorelli C; Spinillo A
Contraception; 2013 Sep; 88(3):369-75. PubMed ID: 23453784
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of a novel oral contraceptive based on oestradiol (oestradiol valerate/dienogest): a Phase III trial.
Palacios S; Wildt L; Parke S; Machlitt A; Römer T; Bitzer J
Eur J Obstet Gynecol Reprod Biol; 2010 Mar; 149(1):57-62. PubMed ID: 19969409
[TBL] [Abstract][Full Text] [Related]
8. Metabolic and haemostatic effects of estradiol valerate/dienogest, a novel oral contraceptive: a randomized, open-label, single-centre study.
Junge W; Mellinger U; Parke S; Serrani M
Clin Drug Investig; 2011; 31(8):573-584. PubMed ID: 21721593
[TBL] [Abstract][Full Text] [Related]
9. Estradiol valerate/dienogest: a novel combined oral contraceptive.
Borgelt LM; Martell CW
Clin Ther; 2012 Jan; 34(1):37-55. PubMed ID: 22169052
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy and safety of combined estradiol valerate and dienogest: a new no-bleed treatment.
von Schoultz B
Climacteric; 2003 Aug; 6 Suppl 2():24-32. PubMed ID: 14669841
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and bleeding profile of a combined oral contraceptive containing oestradiol valerate/dienogest: a pooled analysis of three studies conducted in North America and Europe.
Nelson A; Parke S; Makalova D; Serrani M; Palacios S; Mellinger U
Eur J Contracept Reprod Health Care; 2013 Aug; 18(4):264-73. PubMed ID: 23651474
[TBL] [Abstract][Full Text] [Related]
12. Estradiol valerate plus dienogest versus ethinylestradiol plus levonorgestrel for the treatment of primary dysmenorrhea.
Petraglia F; Parke S; Serrani M; Mellinger U; Römer T
Int J Gynaecol Obstet; 2014 Jun; 125(3):270-4. PubMed ID: 24713413
[TBL] [Abstract][Full Text] [Related]
13. Effect of four oral contraceptives on hemostatic parameters.
Wiegratz I; Lee JH; Kutschera E; Winkler UH; Kuhl H
Contraception; 2004 Aug; 70(2):97-106. PubMed ID: 15288212
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of a combined oral contraceptive containing 0.030 mg ethinylestradiol/2 mg dienogest for the treatment of papulopustular acne in comparison with placebo and 0.035 mg ethinylestradiol/2 mg cyproterone acetate.
Palombo-Kinne E; Schellschmidt I; Schumacher U; Gräser T
Contraception; 2009 Apr; 79(4):282-9. PubMed ID: 19272497
[TBL] [Abstract][Full Text] [Related]
15. Resistance to APC and SHBG levels during use of a four-phasic oral contraceptive containing dienogest and estradiol valerate: a randomized controlled trial.
Raps M; Rosendaal F; Ballieux B; Rosing J; Thomassen S; Helmerhorst F; van Vliet H
J Thromb Haemost; 2013 May; 11(5):855-61. PubMed ID: 23410231
[TBL] [Abstract][Full Text] [Related]
16. Effective treatment of heavy and/or prolonged menstrual bleeding with an oral contraceptive containing estradiol valerate and dienogest: a randomized, double-blind Phase III trial.
Fraser IS; Römer T; Parke S; Zeun S; Mellinger U; Machlitt A; Jensen JT
Hum Reprod; 2011 Oct; 26(10):2698-708. PubMed ID: 21784734
[TBL] [Abstract][Full Text] [Related]
17. Sleep, vigilance and cognition in postmenopausal women: placebo-controlled studies with 2 mg estradiol valerate, with and without 3 mg dienogest.
Saletu B
Climacteric; 2003 Aug; 6 Suppl 2():37-45. PubMed ID: 14669843
[TBL] [Abstract][Full Text] [Related]
18. Pooled analysis of bleeding profile, efficacy and safety of oral oestradiol valerate/dienogest in women aged 25 and under.
Jensen JT; Bitzer J; Nappi RE; Ahlers C; Bannemerschult R; Parke S
Eur J Contracept Reprod Health Care; 2020 Apr; 25(2):98-105. PubMed ID: 32162555
[No Abstract] [Full Text] [Related]
19. Ovulation inhibition with four variations of a four-phasic estradiol valerate/dienogest combined oral contraceptive: results of two prospective, randomized, open-label studies.
Endrikat J; Parke S; Trummer D; Schmidt W; Duijkers I; Klipping C
Contraception; 2008 Sep; 78(3):218-25. PubMed ID: 18692612
[TBL] [Abstract][Full Text] [Related]
20. Effect of four different oral contraceptives on various sex hormones and serum-binding globulins.
Wiegratz I; Kutschera E; Lee JH; Moore C; Mellinger U; Winkler UH; Kuhl H
Contraception; 2003 Jan; 67(1):25-32. PubMed ID: 12521654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
